Importance: More than half of all patients with major depressive disorder (MDD) experience a relapse within 2 years after recovery. It is unclear how relapse affects brain morphologic features during the course of MDD. Objective: To use structural magnetic resonance imaging to identify morphologic brain changes associated with relapse in MDD. Design, Setting, and Participants: In this longitudinal case-control study, patients with acute MDD at baseline and healthy controls were recruited from the University of Münster Department of Psychiatry from March 21, 2010, to November 14, 2014, and were reassessed from November 11, 2012, to October 28, 2016. Depending on patients' course of illness during follow-up, they were subdivided into groups of patients with and without relapse. Whole-brain gray matter volume and cortical thickness of the anterior cingulate cortex, orbitofrontal cortex, middle frontal gyrus, and insula were assessed via 3-T magnetic resonance imaging at baseline and 2 years later. Main Outcomes and Measures: Gray matter was analyzed via group (no relapse, relapse, and healthy controls) by time (baseline and follow-up) analysis of covariance, controlling for age and total intracranial volume. Confounding factors of medication and depression severity were assessed. Results: This study included 37 patients with MDD and a relapse (19 women and 18 men; mean [SD] age, 37.0 [12.7] years), 23 patients with MDD and without relapse (13 women and 10 men; mean [SD] age, 32.5 [10.5] years), and 54 age- and sex-matched healthy controls (24 women and 30 men; mean [SD] age, 37.5 [8.7] years). A significant group-by-time interaction controlling for age and total intracranial volume revealed that patients with relapse showed a significant decline of insular volume (difference, -0.032; 95% CI, -0.063 to -0.002; P = .04) and dorsolateral prefrontal volume (difference, -0.079; 95% CI, -0.113 to -0.045; P < .001) from baseline to follow-up. In patients without relapse, gray matter volume in these regions did not change significantly (insula: difference, 0.027; 95% CI, -0.012 to 0.066; P = .17; and dorsolateral prefrontal volume: difference, 0.023; 95% CI, -0.020 to 0.066; P = .30). Volume changes were not correlated with psychiatric medication or with severity of depression at follow-up. Additional analysis of cortical thickness showed an increase in the anterior cingulate cortex (difference, 0.073 mm; 95% CI, 0.023-0.123 mm; P = .005) and orbitofrontal cortex (difference, 0.089 mm; 95% CI, 0.032-0.147 mm; P = .003) from baseline to follow-up in patients without relapse. Conclusion and Relevance: A distinct association of relapse in MDD with brain morphologic features was revealed using a longitudinal design. Relapse is associated with brain structures that are crucial for regulation of emotions and thus needs to be prevented. This study might be a step to guide future prognosis and maintenance treatment in patients with recurrent MDD.
Importance: More than half of all patients with major depressive disorder (MDD) experience a relapse within 2 years after recovery. It is unclear how relapse affects brain morphologic features during the course of MDD. Objective: To use structural magnetic resonance imaging to identify morphologic brain changes associated with relapse in MDD. Design, Setting, and Participants: In this longitudinal case-control study, patients with acute MDD at baseline and healthy controls were recruited from the University of Münster Department of Psychiatry from March 21, 2010, to November 14, 2014, and were reassessed from November 11, 2012, to October 28, 2016. Depending on patients' course of illness during follow-up, they were subdivided into groups of patients with and without relapse. Whole-brain gray matter volume and cortical thickness of the anterior cingulate cortex, orbitofrontal cortex, middle frontal gyrus, and insula were assessed via 3-T magnetic resonance imaging at baseline and 2 years later. Main Outcomes and Measures: Gray matter was analyzed via group (no relapse, relapse, and healthy controls) by time (baseline and follow-up) analysis of covariance, controlling for age and total intracranial volume. Confounding factors of medication and depression severity were assessed. Results: This study included 37 patients with MDD and a relapse (19 women and 18 men; mean [SD] age, 37.0 [12.7] years), 23 patients with MDD and without relapse (13 women and 10 men; mean [SD] age, 32.5 [10.5] years), and 54 age- and sex-matched healthy controls (24 women and 30 men; mean [SD] age, 37.5 [8.7] years). A significant group-by-time interaction controlling for age and total intracranial volume revealed that patients with relapse showed a significant decline of insular volume (difference, -0.032; 95% CI, -0.063 to -0.002; P = .04) and dorsolateral prefrontal volume (difference, -0.079; 95% CI, -0.113 to -0.045; P < .001) from baseline to follow-up. In patients without relapse, gray matter volume in these regions did not change significantly (insula: difference, 0.027; 95% CI, -0.012 to 0.066; P = .17; and dorsolateral prefrontal volume: difference, 0.023; 95% CI, -0.020 to 0.066; P = .30). Volume changes were not correlated with psychiatric medication or with severity of depression at follow-up. Additional analysis of cortical thickness showed an increase in the anterior cingulate cortex (difference, 0.073 mm; 95% CI, 0.023-0.123 mm; P = .005) and orbitofrontal cortex (difference, 0.089 mm; 95% CI, 0.032-0.147 mm; P = .003) from baseline to follow-up in patients without relapse. Conclusion and Relevance: A distinct association of relapse in MDD with brain morphologic features was revealed using a longitudinal design. Relapse is associated with brain structures that are crucial for regulation of emotions and thus needs to be prevented. This study might be a step to guide future prognosis and maintenance treatment in patients with recurrent MDD.
Authors: Susan M Resnick; Dzung L Pham; Michael A Kraut; Alan B Zonderman; Christos Davatzikos Journal: J Neurosci Date: 2003-04-15 Impact factor: 6.167
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: Leila Haddad; Axel Schäfer; Fabian Streit; Florian Lederbogen; Oliver Grimm; Stefan Wüst; Michael Deuschle; Peter Kirsch; Heike Tost; Andreas Meyer-Lindenberg Journal: Schizophr Bull Date: 2014-06-03 Impact factor: 9.306
Authors: Warren D Taylor; Douglas R McQuoid; Martha E Payne; Anthony S Zannas; James R MacFall; David C Steffens Journal: Am J Geriatr Psychiatry Date: 2013-11-22 Impact factor: 4.105
Authors: L Schmaal; D P Hibar; P G Sämann; G B Hall; B T Baune; N Jahanshad; J W Cheung; T G M van Erp; D Bos; M A Ikram; M W Vernooij; W J Niessen; H Tiemeier; A Hofman; K Wittfeld; H J Grabe; D Janowitz; R Bülow; M Selonke; H Völzke; D Grotegerd; U Dannlowski; V Arolt; N Opel; W Heindel; H Kugel; D Hoehn; M Czisch; B Couvy-Duchesne; M E Rentería; L T Strike; M J Wright; N T Mills; G I de Zubicaray; K L McMahon; S E Medland; N G Martin; N A Gillespie; R Goya-Maldonado; O Gruber; B Krämer; S N Hatton; J Lagopoulos; I B Hickie; T Frodl; A Carballedo; E M Frey; L S van Velzen; B W J H Penninx; M-J van Tol; N J van der Wee; C G Davey; B J Harrison; B Mwangi; B Cao; J C Soares; I M Veer; H Walter; D Schoepf; B Zurowski; C Konrad; E Schramm; C Normann; K Schnell; M D Sacchet; I H Gotlib; G M MacQueen; B R Godlewska; T Nickson; A M McIntosh; M Papmeyer; H C Whalley; J Hall; J E Sussmann; M Li; M Walter; L Aftanas; I Brack; N A Bokhan; P M Thompson; D J Veltman Journal: Mol Psychiatry Date: 2016-05-03 Impact factor: 15.992
Authors: Tilo Kircher; Markus Wöhr; Igor Nenadic; Rainer Schwarting; Gerhard Schratt; Judith Alferink; Carsten Culmsee; Holger Garn; Tim Hahn; Bertram Müller-Myhsok; Astrid Dempfle; Maik Hahmann; Andreas Jansen; Petra Pfefferle; Harald Renz; Marcella Rietschel; Stephanie H Witt; Markus Nöthen; Axel Krug; Udo Dannlowski Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-09-28 Impact factor: 5.270
Authors: Susanne Meinert; Jonathan Repple; Igor Nenadic; Axel Krug; Andreas Jansen; Dominik Grotegerd; Katharina Förster; Verena Enneking; Katharina Dohm; Simon Schmitt; Frederike Stein; Katharina Brosch; Tina Meller; Ronny Redlich; Joscha Böhnlein; Lisa Sindermann; Janik Goltermann; Elisabeth J Leehr; Nils Opel; Leni Aldermann; Andreas Reuter; Ricarda I Schubotz; Tim Hahn; Tilo Kircher; Udo Dannlowski Journal: Neuropsychopharmacology Date: 2019-08-05 Impact factor: 7.853
Authors: Frederike Stein; Tina Meller; Katharina Brosch; Simon Schmitt; Kai Ringwald; Julia Katharina Pfarr; Susanne Meinert; Katharina Thiel; Hannah Lemke; Lena Waltemate; Dominik Grotegerd; Nils Opel; Andreas Jansen; Igor Nenadić; Udo Dannlowski; Axel Krug; Tilo Kircher Journal: Schizophr Bull Date: 2021-10-21 Impact factor: 9.306